PHARMACEUTICAL IP

  • Offering
    • Evolve AI
      • Albert (Validity)
        • Validity analysis
        • Albert Construe (Claim construction)
      • Popper (Prosecution)
      • Franklin (Publication review)
      • AI for Sequences
    • Fractional IP counsel
    • Services
      • AI guidance
      • Competitive intelligence
      • Deals
      • Due diligence
      • Freedom to operate
      • IP strategy and communication
      • Oppositions and appeals
      • Patent drafting
      • Patent prosecution
      • Trade secrets
    • Technologies
      • Pharmaceuticals
      • Biologics
      • Cell & gene therapy
      • AI drug discovery
    • Our clients
      • Biotech
      • CROs and CMOs
      • Established pharma
      • International IP counsel
      • Investors
      • Start-ups
      • Universities
  • Fractional IP counsel
    • Fractional IP counsel
    • What is fractional IP counsel?
    • Our clients
      • Biotech
      • CROs and CMOs
      • Established pharma
      • International IP counsel
      • Investors
      • Start-ups
      • Universities
  • Evolve AI
    • Albert (Validity)
      • Validity analysis
      • Albert Construe (Claim construction)
    • Popper (Prosecution)
    • Franklin (Publication review)
    • AI for Sequences
  • Technologies
    • Pharmaceuticals
      • Dosing regimens
      • Formulations
      • Life cycle management
      • New indications
      • Platform technologies
    • Biologics
      • Antibodies
      • Antibody-drug conjugates (ADCs)
      • T cell engagers (TCEs)
    • Cell & gene therapy
      • CAR-T cell therapies
      • Gene therapies
      • In vivo CAR-T
      • Lipid nanoparticles (LNPs)
      • Macrophages (CAR-M)
      • mRNA therapeutics
      • Regenerative cell therapies
    • AI drug discovery
  • Insights
    • Articles
    • Pharma IP Toolkit
    • Evolve Guides
    • Events & Webinars
    • Subscribe
  • About us
    • Our team
    • Recognition
    • Join us
    • Contact us
  • Offering
    • Evolve AI
      • Albert (Validity)
        • Validity analysis
        • Albert Construe (Claim construction)
      • Popper (Prosecution)
      • Franklin (Publication review)
      • AI for Sequences
    • Fractional IP counsel
    • Services
      • AI guidance
      • Competitive intelligence
      • Deals
      • Due diligence
      • Freedom to operate
      • IP strategy and communication
      • Oppositions and appeals
      • Patent drafting
      • Patent prosecution
      • Trade secrets
    • Technologies
      • Pharmaceuticals
      • Biologics
      • Cell & gene therapy
      • AI drug discovery
    • Our clients
      • Biotech
      • CROs and CMOs
      • Established pharma
      • International IP counsel
      • Investors
      • Start-ups
      • Universities
  • Fractional IP counsel
    • Fractional IP counsel
    • What is fractional IP counsel?
    • Our clients
      • Biotech
      • CROs and CMOs
      • Established pharma
      • International IP counsel
      • Investors
      • Start-ups
      • Universities
  • Evolve AI
    • Albert (Validity)
      • Validity analysis
      • Albert Construe (Claim construction)
    • Popper (Prosecution)
    • Franklin (Publication review)
    • AI for Sequences
  • Technologies
    • Pharmaceuticals
      • Dosing regimens
      • Formulations
      • Life cycle management
      • New indications
      • Platform technologies
    • Biologics
      • Antibodies
      • Antibody-drug conjugates (ADCs)
      • T cell engagers (TCEs)
    • Cell & gene therapy
      • CAR-T cell therapies
      • Gene therapies
      • In vivo CAR-T
      • Lipid nanoparticles (LNPs)
      • Macrophages (CAR-M)
      • mRNA therapeutics
      • Regenerative cell therapies
    • AI drug discovery
  • Insights
    • Articles
    • Pharma IP Toolkit
    • Evolve Guides
    • Events & Webinars
    • Subscribe
  • About us
    • Our team
    • Recognition
    • Join us
    • Contact us
  • Offering
  • What is fractional IP counsel?
  • Evolve AI
  • Technologies
  • Insights
  • Our team
  • Offering
  • What is fractional IP counsel?
  • Evolve AI
  • Technologies
  • Insights
  • Our team

Alice Walford joins Evolve

  • Technology: Patent law
  • 1st July 2026
Alice Walford Patent Attorney

We are delighted to welcome Alice Walford to the Evolve team.

Alice joins us with over 15 years of combined private practice and in-house experience in the life sciences sector. Alice brings a wealth of experience, including time at Novartis, Gyroscope Therapeutics and Abzena, working on gene therapies, small molecule and antibody assets. Her specialist knowledge further strengthens our ability to provide strategic and forward-thinking advice, as we continue to support innovation in the pharmaceutical industry.

Welcome aboard Alice!

Related insights...

Swarm of gold spheres with one large turquoise sphere at the centre on dark blue, Evolve abstract article image
Swarm of gold spheres with one large turquoise sphere at the centre on dark blue, Evolve abstract article image

Evolve’s Claudia Greaves earns CIPA Advanced Patent Paralegal Qualification

  • 9th January 2026
We are delighted to announce that Evolve’s Claudia Greaves has recently passed the CIPA Advanced Patent Paralegal Course (APPC). Building on her six years of patent law experience, Claudia completed intensive modules that deepen her expertise in critical areas of IP management: The Patent Cooperation Treaty (PCT): Gaining in-depth understanding of both the International Phase…
Swarm of gold spheres with one large turquoise sphere at the centre on dark blue, Evolve abstract article image
Swarm of gold spheres with one large turquoise sphere at the centre on dark blue, Evolve abstract article image

Evolve Intellectual Property celebrates 4 years!

  • 8th October 2025
Last month, Evolve celebrated its 4-year anniversary in style with a sparkling wine and canapés reception in Cambridge. Thank you to everyone who attended and for our clients’ continued trust and support. We look forward to many more years of helping our clients in their mission to deliver innovative medicines to market and bring hope…
Swarm of gold spheres with one large turquoise sphere at the centre on dark blue, Evolve abstract article image
Swarm of gold spheres with one large turquoise sphere at the centre on dark blue, Evolve abstract article image

Launch of Evolve Webinars!

  • 25th June 2025
A series of live webinars on IP strategy for pharma & biotech professionals.
Flight of gold steps with one turquoise glowing step on dark blue, Evolve abstract article image
Flight of gold steps with one turquoise glowing step on dark blue, Evolve abstract article image

Evolve’s Steven Gurney recognised in IAM 1000 2025

  • 11th June 2025
We are delighted to announce that Evolve’s founder Steven Gurney has once again been recognised in the IAM Patent 1000.
Swarm of gold spheres with one large turquoise sphere at the centre on dark blue, Evolve abstract article image
Swarm of gold spheres with one large turquoise sphere at the centre on dark blue, Evolve abstract article image

Event report: C5 Pharma & Biotech Patent Litigation in Europe (Day 1), Plausibility, UPC and antibody IP strategy

  • 27th May 2025
Navigating European pharma and biotech patent litigation is more complex than ever, with ongoing debates on plausibility, UPC intricacies, claim interpretation, and divergent strategies for antibody inventions.
Rose Hughes
Rose Hughes

Rose Hughes joins Evolve

  • 7th May 2025
Evolve Intellectual Property is pleased to welcome Dr. Rose Hughes as our new Patent Attorney.
Gold strands braiding into one cord with a turquoise join on dark blue, Evolve abstract article image
Gold strands braiding into one cord with a turquoise join on dark blue, Evolve abstract article image

Evolve joins the ranks of the Legal 500

  • 1st November 2024
We are delighted to announce that Evolve has joined the ranks of the Legal 500 Intellectual Property firms. The Legal 500 is one of the UK’s leading legal directories, known for its rigorous research methodology and independent analysis of the legal market. As a small boutique IP firm, we are particularly proud of this achievement. …
All Insights

evolve® is a trading entity of Evolve Intellectual Property Limited. Evolve Intellectual Property Limited is regulated by the Intellectual Property Regulation Board (IPReg). Details of the UK professional rules can be found on the IPReg website

registered address: 49 Greek Street, London, England, W1D 4EG

website out of house

© 2026 All Rights Reserved

Keep in touch

  • Subscribe
  • Contact us
  • Cookie Notice
  • Complaints Procedure
  • Privacy notice
  • Subscribe
  • Contact us
  • Cookie Notice
  • Complaints Procedure
  • Privacy notice